首页> 外文期刊>The journal of clinical psychiatry >Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.
【24h】

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.

机译:前两周的早期改善可作为重度抑郁症患者治疗结局的预测指标:一项荟萃分析,纳入6562名患者。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought.
机译:目的:新证据表明,在治疗2周后可以高度敏感地预测治疗反应。在这里,我们评估抗抑郁治疗的早期改善是否可以预测重度抑郁症(MDD)患者的治疗结果。数据来源:进行了41项临床试验,将米氮平与活性比较剂或安慰剂在住院患者和门诊患者(全部治疗的人群,N = 6907;意向治疗人群,N = 6562)与MDD(DSM-III-R或DSM)中进行了比较-IV标准)在治疗的2周内检查了早期改善(在17个项目的汉密尔顿抑郁量表[HAM-D-17]上,与基线相比降低了20%以上)以及与治疗效果的关系。研究选择:数据来自对单盲或双盲临床试验的系统搜索(临床试验数据库,Organon,先灵a雅公司的一部分,荷兰奥斯)。所有纳入的试验(共41项)均采用抗抑郁药治疗超过4周,最多8周。研究范围为1982年3月至2003年12月。如果没有可用的HAM-D-17分级,没有诊断MDD或没有盲目研究,则排除试验。如果在第2周,第4周和第4周之后至少进行一次HAM-D-17评估,则也排除了试验。分别大于或等于87%)。利用米氮平的快速滴定与缓慢滴定进行的研究表明,对于稳定的应答者(98%,[95%CI = 93%至100%],相对于91%[95%CI = 89%至93%]),灵敏度更高(100%,[95%CI = 92%至100%],而93%[95%CI = 91%至95%])。稳定的响应者和稳定的汇款者的阴性预测值比阳性预测值(范围= 19%-60%)高得多(范围= 82%-100%)。结论:这些结果表明抗抑郁药物的早期改善可以预测重度抑郁症患者的后续治疗结果,并具有较高的敏感性。高阴性预测值表明在2周内没有改善的情况下,稳定反应或稳定缓解的机会很小。在治疗的前两周内没有改善可能表明抑郁症管理的改变应比传统上认为的要早。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号